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Lysosomotropism depends on glucose: a chloroquine
resistance mechanism
Laura E Gallagher1, Ohood A Radhi1, Mahmud O Abdullah1, Anthony G McCluskey1, Marie Boyd1 and Edmond YW Chan*,1
There has been long-standing interest in targeting pro-survival autophagy as a combinational cancer therapeutic strategy. Clinical
trials are in progress testing chloroquine (CQ) or its derivatives in combination with chemo- or radiotherapy for solid and
haematological cancers. Although CQ has shown efficacy in preclinical models, its mechanism of action remains equivocal. Here,
we tested how effectively CQ sensitises metastatic breast cancer cells to further stress conditions such as ionising irradiation,
doxorubicin, PI3K-Akt inhibition and serum withdrawal. Contrary to the conventional model, the cytotoxic effects of CQ were found
to be autophagy-independent, as genetic targeting of ATG7 or the ULK1/2 complex could not sensitise cells, like CQ, to serum
depletion. Interestingly, although CQ combined with serum starvation was robustly cytotoxic, further glucose starvation under
these conditions led to a full rescue of cell viability. Inhibition of hexokinase using 2-deoxyglucose (2DG) similarly led to CQ
resistance. As this form of cell death did not resemble classical caspase-dependent apoptosis, we hypothesised that CQ-mediated
cytotoxicity was primarily via a lysosome-dependent mechanism. Indeed, CQ treatment led to marked lysosomal swelling and
recruitment of Galectin3 to sites of membrane damage. Strikingly, glucose starvation or 2DG prevented CQ from inducing
lysosomal damage and subsequent cell death. Importantly, we found that the related compound, amodiaquine, was more potent
than CQ for cell killing and not susceptible to interference from glucose starvation. Taken together, our data indicate that CQ
effectively targets the lysosome to sensitise towards cell death but is prone to a glucose-dependent resistance mechanism, thus
providing rationale for the related compound amodiaquine (currently used in humans) as a better therapeutic option for cancer.
Cell Death and Disease (2017) 8, e3014; doi:10.1038/cddis.2017.416; published online 24 August 2017
During macroautophagy (referred to herein as autophagy),
cellular components are sequestered into double-bilayer
membrane vesicles termed autophagosomes. Autophago-
somes next undergo fusion with lysosomes to allow content
degradation and recycling of metabolic building blocks to
sustain cell viability.1 Autophagy generally helps promote
cancer progression.2–4 Autophagy maintains a healthy pool of
mitochondria, for example, in K-Ras dependent tumours5,6 to
support oxidative metabolism, fatty-acid oxidation and gen-
eration of anabolic precursors.1,7Autophagy also helps cancer
cells endure chemo- and radiotherapy, thereby contributing
towards resistance.8–10 As such, autophagy inhibitors are
being investigated to enable better treatment of tumours.
Chloroquine (CQ) or its derivative hydroxychloroquine
(HCQ) has been widely tested in preclinical cancer models
as an inhibitor of the autophagy–lysosomal pathway. These
antimalarial drugs have been attractive candidates for
repurposing in cancer because of their low cost, oral
availability and FDA approval. Initially, clear inhibitory effects
from CQ were shown in a number of haematological
cancers.11–13 Beneficial effects of CQ have been demon-
strated for other solid cancer models.8,14–19 This body of
evidence has supported over 70 clinical trials assessing safety
and efficacy using CQ or HCQ (www.Clinicaltrials.gov).2Other
strategies have explored CQ derivatives.20–23
Despite the substantial testing of CQ in cancer patients, its
mechanism of action remains controversial. CQ was initially
proposed as an autophagy inhibitor and this notion still
persists.24 CQ acts as a weak base and accumulates in the
lysosomes to quench the acidic pH,25 thereby halting
autophagic degradative flux. However, CQ could be targeting
cancer cells via autophagy-independent pathways.19,26–28
Here, we studied CQ in an aggressive metastatic breast
cancer model. CQ sensitised cells to a number of cell
stressors and we found that CQ mediated cell killing
independently of autophagy. In exploring metabolic stress,
we discovered an unexpected mechanism of cellular resis-
tance linking CQ sensitivity to glucose utilisation. We further
identified that amodiaquine (AQ), a related anticancer quino-
line, engages a mechanism distinct from CQ that is not
inhibited by changes in glucose metabolism, thereby high-
lighting a potentially improved anticancer treatment strategy.
Results
CQ sensitises cells to a range of cellular stressors. CQ
use in breast cancer has shown promise, but the full potential
remained unclear.9,14,26,29 As such, we explored combina-
tions of CQ with range of anticancer treatments using 4T1
metastatic breast cancer cells. Incubation with CQ for 24 h
only led to marginal (o15%) killing of 4T1 cells as detected
by clonogenic survival (Figure 1a). Similarly, treatment of
cells with 0–10 Gy X-irradiation alone induced only low-level,
but dose-dependent, cytotoxicity in 4T1 cells (o40% killing
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after administration of the highest 10 Gy dose). However,
incubation with CQ significantly sensitised cells to 4 or 10 Gy
irradiation doses.
As CQ can sensitise to loss of PI3K/MTOR signalling,30–32
we further examined this combination in 4T1 cells. Inhibition of
PI3K/MTOR, through serum starvation for 24 h, did not
substantially reduce cell viability (Figure 1b). However, CQ
enhanced levels of cytotoxicity produced from serum with-
drawal. The dual PI3K/MTOR inhibitor NVP-BEZ235 acts
as a robust anticancer compound, particularly for breast
cancer.33–37 Here, BEZ235 alone was cytotoxic in 4T1 cells in
a dose-dependent manner (Figure 1c). However, cytotoxicity
for each dose of BEZ235 was potentiated by greater than
threefold via co-addition of CQ. These findings show that CQ
can strongly potentiate the cell death caused by DNA-
damaging and growth factor deprivation stress conditions in
breast cancer cells.
CQ decreases viability via an autophagy- and apoptosis-
independent mechanism. CQ acts as a weak base to de-
acidify the lysosome,25 thereby inhibiting autophagic degra-
dative flux. However, the relationship between CQ-mediated
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Figure 1 CQ sensitises 4T1 cells to ionising radiation, MTOR-PI3K inhibition and growth factor/serum depletion. (a) 4T1 cells were exposed to irradiation (1–10 Gray) and
incubated ±CQ (25 μM) as indicated for 24 h. After this treatment, drug-free media were replenished and viability was assessed by clonogenic growth and quantified. Viability
expressed as clonogenic index where control (no CQ) represents 100% (n= 3 experiments± S.E.M.). ***Po0.001 by one-way ANOVA as compared with no CQ at equivalent
irradiation. (b) Cells were incubated in full-nutrient or serum-free DMEM ±CQ (25 μM) for 24 h. Cells were then replenished with full-nutrient drug-free growth media and
assessed for viability (n= 3 experiments± S.E.M.). ***Po0.001 by one-way ANOVA as compared with no CQ serum-starved condition. (c) Cells were treated with the dual
MTOR/PI3K inhibitor (NVP-BEZ-235) at increasing doses ±CQ for 24 h. Full-nutrient drug-free growth media were replenished and cells were assessed for viability (n= 3
experiments± S.E.M.). *Po0.05 by one-way ANOVA as compared with paired no CQ serum condition under same NVP-BEZ-235 dose
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cell viability and autophagy has become
controversial.18,19,26–28 Here, we observed that CQ robustly
inhibited the autophagy flux in 4T1 cells as observed through
the accumulation of LC3 and p62/SQSTM1 protein and
autophagy membrane structures staining positive for LC3 or
p62/SQSTM1 (Figures 2a and b). Cells with autophagy
inhibition were generally viable for up to 72 h under CQ
treatment with sustained LC3 accumulation and no overt cell
loss. Autophagy inhibition could, therefore, be tolerated
without causing cytotoxicity.
To clarify whether CQ was decreasing cell viability through
autophagy, we used shRNA to stably knockdown ATG7 in 4T1
cells.2,7 4T1 cells lacking ATG7 were fully defective for basal
and starvation-induced LC3 lipidation (Figures 2c–e). Despite
this complete block, 4T1/shATG7 cellswere notmore sensitive
than wild-type 4T1 to serum starvation stress (Figure 2f). 4T1/
shATG7 cells additionally retained sensitivity to CQ-induced
cytotoxicity, both alone, or when combined with serum
starvation (Figure 2g). As such, CQ led to cytotoxicity
independently of autophagy. To investigate CQ-induced
cytotoxicity in a different system, we used ULK1/2 double
knockout (DKO) mouse embryonic fibroblasts (MEFs) that are
defective in nutrient-sensitive autophagy (Figure 2h).38 We
confirmed that wild-type MEF displayed sensitivity to CQ-
induced cytotoxicity, in particular, under combination with
serum starvation (Figure 2i). Loss of autophagy in ULK1/2
DKO MEF did not make them more sensitive to serum
starvation. Furthermore, CQ combined with serum starvation
still produced cell killing in ULK1/2-deficient cells. These data
highlight that genetic targeting of autophagy does not sensitise
cells to stress conditions in the same way as CQ. In addition,
CQ-induced cell killing does not require autophagy.
CQ and related compounds, particularly in combination with
BEZ235, have been reported to activate apoptosis.31,39–41
Either CQ or serum starvation alone in 4T1 cells led to low
levels of caspase 3 activation and PARP cleavage (Figure 3a).
Combination of CQ with serum starvation led to stronger
caspase 3 activation, and all these apoptotic signalling
responses were blocked by the inhibitor z-DEVD-FMK.
However, z-DEVD-FMK could not reverse the cytotoxicity
produced by CQ alone or when combined with serum
starvation (Figure 3b).
As inhibition of caspase 3 did not ameliorate cell kill, we
tested whether CQ invoked necroptosis, another mode of
programmed cell death.42–45 Necroptosis can be pharmaco-
logically probed by necrostatin-1, which inhibits receptor-
interacting kinase 1. Addition of necrostatin-1 was unable to
rescue viability of 4T1 cells treated to CQ combined with
serum starvation (Figure 3c). CQ and other lysosome-
targeting agents have been associated with reactive-oxygen
species (ROS) contribution towards cell death.41,44,46,47
However, addition of free radical scavenger N-acetyl cysteine
was unable to rescue cells treated to CQ combined with serum
starvation (Figure 3d). Thus, CQ-mediated cytotoxicity was
occurring independently of apoptosis, necroptosis, autophagy
and ROS.
Glucose starvation causes resistance to CQ-mediated
cell killing. As aggressive cancer cells (such as 4T1)
become addicted to nutrients,24 we explored starvation and
responses to CQ. We compared the following: (1) serum
starvation; (2) serum and glucose starvation; and (3) serum
and amino-acid starvation – all in the presence or absence of
CQ. As control, we confirmed loss of cell viability when CQ is
combined with serum withdrawal. Unexpectedly, further
withdrawal of glucose, in the context of serum starvation,
fully rescued the effect of CQ (Figures 4a and b). In contrast,
withdrawal of amino acids and serum together promoted CQ-
mediated cytotoxicity. CQ and nutrient starvation required
more than 8 h to produce cytotoxicity. Incubation under the
most stressful condition (serum and amino-acid starvation
+CQ) produced 450% decreases in cell viability only after
relatively long (16 h) incubation (Figure 4c). By comparison,
glucose starvation and serum starvation (with CQ) did not
lead to cell killing under the same timeframe. We confirmed
that glucose starvation similarly protected wild-type and
ULK1/2 DKO MEF from CQ-mediated cytotoxicity
(Supplementary Figure 1).
Nutrient starvation combined with CQ seemed to be killing
cells independently of classical apoptosis and necroptosis. To
gain further insight into the underlying cell death, we
monitored cell morphology by hourly live-cell imaging
(Figure 4d and Supplementary Movies). Consistent with the
viability time course, 4T1 cells incubated in serum starvation
+CQ appeared morphologically normal for up to 16 h, after
which cells exhibited rounding, condensation and detach-
ment. Starvation of glucose along with serum blocked these
CQ-induced changes. Quantitation of cell growth highlighted
the varying responses to nutrients and CQ (Figure 4e). Serum
starvation alone (top panel) was generally tolerated, with a
mild decrease in cell growth over the 24-h starvation period.
Cell growth was more strongly suppressed by combined
glucose and serum starvation. Under combined amino-acid
and serum starvation, reduced cell growth was displayed for
12 h, after which there was a further decline in cell prolifera-
tion, presumably after glucose had also been depleted.
Interestingly, after all these 24-h starvation stress conditions,
cells returned to a rapidly dividing state after replenishment of
nutrients.
CQ treatment alone was non-toxic (bottom panel). By
contrast, combination of CQ with any of the starvation
conditions led to clear cell targeting within 12–18 h. As
expected, cells stressed with CQ and serum starvation (or
serum and amino-acid starvation) did not recover following
replenishment of full nutrient drug-free media. However, cells
that had glucose starvation showed resistance to CQ and
recovered after nutrient replenishment and removal of CQ.
2-Deoxyglucose mimics glucose starvation in causing
resistance. In 4T1 cells, glucose starvation offered protec-
tion from CQ coupled with serum starvation. To further
explore this relationship, we examined the glycolysis inhibitor,
2-deoxyglucose (2DG). 2DG becomes phosphorylated in
cells to generate 2DG-6-phosphate, which inhibits the
glycolytic enzymes hexokinase and phosphoglucose
isomerase.48 Interestingly, addition of 2DG significantly
promoted survival of cells under the stress of CQ in
combination with serum starvation (Figure 5a). We tested
whether other glycolysis inhibitors could confer the same
protective advantage as 2DG. However, neither Gossypol
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(inhibitor of lactate dehydrogenase) nor dichloroacetate
(inhibitor of pyruvate dehydrogenase kinase) was able to
rescue 4T1 cell viability from CQ and serum starvation
(Supplementary Figure 2A). 2DG is therefore the best
pharmacologic agent so far tested that mimics glucose
starvation in preventing the cytotoxicity of CQ.
Energy depletion activates an AMPK-dependent metabolic
cell-cycle checkpoint that also promotes cell survival.49–53
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Therefore, we tested whether increased cell survival upon
glucose starvation was driven by AMPK. However, co-
incubation with AICAR to activate AMPK did not rescue cell
viability (Supplementary Figure 2B). We further questioned
whether increased survival was due to overall suppressed
levels of metabolism. We tested the cell-permeable intermedi-
ate, methyl pyruvate (MP), which is converted to acetyl-CoA to
drive oxidative phosphorylation.54 As an alternate test, we
supplemented glucose starvation conditions with galactose to
promote oxidative phosphorylation.55 However, addition of
neither MP nor galactose supplementation affected the cell
viability rescue provided from glucose deprivation (Figure 5b).
In order to survive during the 24-h glucose starvation CQ
treatment period, cells must utilise other nutrient sources. A
fundamental feature of cancer cells is heavy reliance on
glutamine.24,56,57 We hypothesised that 4T1 cells metabolise
glutamine to survive the glucose starvation period. Again, in
the controls, cells starved of glucose displayed increased
survival in response to CQ and serum starvation (Figure 5c).
However, further withdrawal of glutamine (in glucose- and
serum-free conditions, with CQ) led to complete loss
of cell viability. Glutamine-free starvation was notably not
cytotoxic in the absence of CQ. These data highlight
that 4T1 cells have a strong reliance on glutamine for
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Figure 3 CQ triggers apoptosis- and necroptosis-independent 4T1 cell death. (a) Cells were starved of serum (-S) ±CQ (25 μM) for 24 h. Where indicated, Z-DEVD-FMK
(10 μM) was included. Immunoblotting confirmed PARP and caspase 3 cleavage following CQ treatment combined with serum starvation. (b) Cells were starved of serum ±CQ
(25 μM) in the presence of Z-DEVD-FMK (10 μM), as indicated, for 24 h. After treatments, clonogenic viability was measured. Z-DEVD-FMK did not significantly (N.S.) rescue
cell viability despite blocking caspase 3 activation. (c) Cells were starved of serum ±CQ (25 μM) in the presence of Necrostatin-1 (20 μM), as indicated, for 24 h. The
necroptosis inhibitor did not rescue cell viability. (d) Cells were starved of serum ±CQ (25 μM) in the presence of N-acetyl-cysteine (10 mM), as indicated, for 24 h. ROS
scavenger did not rescue cell viability
Figure 2 CQ sensitisation to cell death is independent of autophagy. (a) 4T1 cells were treated under full nutrient conditions with CQ (25 μM) for up to 72 h. Cell lysates were
analysed for LC3 and Sequestosome 1/p62 protein levels by immunoblotting. Quantification is expressed as fold change in LC3-II/actin or p62/actin. (b) 4T1 cells were treated as
above with CQ for 24 h and stained for LC3- and p62-associated membranes. (c–e) 4T1 cells expressing ATG7 shRNA were treated to amino-acid starvation (EBSS incubation)
for 2 h. Cell lysates were analysed for ATG7 levels and lipidation of LC3 (c) or autophagosome number by staining for LC3 (d; scale bars: 10 μm). Autophagosomes in wild-type or
shATG7-4T1 cells were quantified (expressed as mean± S.D. from480 cells; two experiments). ***Po0.001 by paired t-test as compared with wild-type starved cells. (f) Wild-
type or shATG7-expressing 4T1 cells were incubated in full-nutrient (Ctrl) or serum-free DMEM for 24 h before exchange back into fresh full-nutrient media to assess clonogenic
viability. Genetic targeting of autophagy did not sensitise cells to serum starvation. All viability shown as Clonogenic Index relative to control (n= 3 experiments ± S.E.M.).
(g) Wild-type (left) or shATG7-(right) expressing 4T1 cells were incubated in full-nutrient (Ctrl) or serum-free DMEM ±CQ (25 μM) for 24 h before exchange back into fresh full-
nutrient media to assess clonogenic viability. ***Po0.001 by one-way ANOVA as compared with paired no CQ condition. CQ shows efficacy in autophagy-deficient 4T1 cells.
(h) Wild-type or ULK1/2 DKO MEFs were analysed for LC3 autophagosome number following 1.5 h starvation in EBSS as in (d and e). Mean± S.D. from490 cells; three
experiments. ***Po0.001 by paired t-test as compared with wild-type starved cells. (i) Wild-type or ULK1/2 DKO MEFs were analysed as in (g). Genetic targeting of autophagy
did not sensitise MEF, and ULK1/2-deficient cells are still targeted by CQ
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survival, particularly when starved of other carbon sources
such as glucose.
CQ leads to lysosomal swelling via a glucose-dependent
pathway. As glucose starvation blocked CQ-mediated cell
killing, we questioned whether effects of CQ on the lysosome
were similarly glucose-dependent. We studied lysosomal
morphology in cells following CQ treatment and nutrient
starvation (Figure 6a). Control 4T1 cells showed abundant
lysosomes with normal morphology. By contrast, CQ
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Figure 4 Glucose starvation rescues CQ-dependent cell death. (a and b) 4T1 cells were incubated in four different nutrient conditions: (1) full-nutrient DMEM (Ctrl); (2)
serum-free DMEM; (3) serum- and glucose-free DMEM; or (4) serum- and amino-acid-free media (EBSS); ±CQ (25 μM) as indicated. After 24 h incubation, clonogenic cell
viability was measured (% of control, n= 3 experiments±S.E.M.). ***Po0.001 by one-way ANOVA. (c) 4T1 cells were treated with the indicated nutrient conditions ±CQ for
4–16 h and then measured for cell viability as in (a) (n= 3 experiments± S.E.M.). (d and e) 4T1 cell growth and morphology were monitored using live-cell imaging during
nutrient and CQ treatments as indicated. (d) Images shown from the 23 h time point. Arrows indicate CQ-induced cell condensation and death. Arrowhead indicates vacuolated
cell death. (e) Cell viability (% of imaging area containing cells, average ± S.E.M., N= 2 experiments) are shown over the 48 h experiment. After 24 h nutrient ±CQ treatments,
full-nutrient drug-free media was replenished (arrow) and cells were further monitored
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treatment produced markedly swollen lysosomes with strong
LAMP-1 staining (Figure 6b). Serum starvation did not affect
lysosomal enlargement caused by CQ. However, combined
glucose and serum starvation fully blocked the ability of CQ to
cause lysosomal swelling. We confirmed that solely glucose
starvation was sufficient to reverse CQ-mediated lysosomal
swelling (Supplementary Figure 3).
We examined whether the mechanism linking CQ efficacy
and glucose metabolism was conserved. We tested UVW
glioma cells, as CQ treatment has been used in glioblastoma
therapy.58,59 UVW cells exhibited similar lysosomal swelling
following CQ treatment, which was further blocked by glucose
starvation (Figure 6c). This inter-relationship was not limited to
cancer cells. Wild-type and ULK1/2 DKO MEF showed typical
normal-sized lysosomes under control and nutrient starvation
conditions (Figures 6d and e). Here, CQ treatment also led to
lysosomal swelling, which could be blocked by glucose
starvation. Above, we showed that the glycolysis inhibitor,
2DG, rescued cytotoxicity driven by CQ. Therefore, we
examined whether 2DG prevented CQ-mediated lysosomal
swelling (Figure 6f). Indeed, 2DG, either at 2.5 and 5 mM,
significantly blocked the ability of CQ to induce lysosomal
swelling. Altogether, the data highlight how CQ induces a
marked lysosomal enlargement in cancer cells, wild-type MEF
and autophagy-deficient MEF. In each of these cell systems,
glucose starvation blocks the ability of CQ to induce lysosomal
swelling. Furthermore, 2DG is able to mimic glucose starva-
tion to block CQ effects on the lysosome.
As glucose starvation prevented CQ from swelling the
lysosome, we hypothesised that CQ might be unable to
access the lysosomal lumen. For example, glucose starvation
might deplete cellular energy and reduce the lysosomal
acidification gradient required to trap CQ. To monitor
lysosomal pH, we used Lysotracker Red to selectively stain
acidic vesicles (Figure 6g). In 4T1 cells, serum starvation
increased lysosomal acidification. Lysosomal acidification
was still maintained upon further glucose or amino-acid
starvation. Importantly, addition of CQ completely ablated
Lysotracker Red staining under basal and all starvation
conditions. Therefore, CQ was still effectively targeting
lysosomal acidification, even under the glucose starvation
condition that blocks lysosomal swelling.
Doxorubicin cytotoxicity is enhanced by CQ but is
independent of glycolysis. Doxorubicin is a widely used
therapeutic in breast cancer, but lysosomal sequestration of
this drug can lead to resistance.60,61 As we observed that CQ
disrupted severely lysosomal homeostasis, we investigated
the interaction between these two forms of chemotherapy. CQ
markedly enhanced the sensitivity of 4T1 cells to doxorubicin
(Figure 7a). However, inhibition of the glucose flux with 2DG
did not lead to any resistance towards doxorubicin (Figure 7b).
Mechanism of CQ is distinct from classical lysosomal-
membrane permeabilisation. The correlation between
lysosomal swelling and cell death suggested lysosomal
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Figure 5 Inhibition of hexokinase rescues CQ-dependent cell death. (a) 4T1 cells were treated with full-nutrient DMEM or serum-free DMEM, in the presence of 2DG (5 mM)
±CQ (25 μM) as indicated, for 24 h. After this incubation, cell clonogenic viability was measured (n= 3 experiments ± S.E.M.). ***Po0.001 by one-way ANOVA. (b) Cells were
treated with serum-free DMEM, or serum-free and glucose-free DMEM+CQ (25 μM) for 24 h, followed by cell viability measurements. Where indicated, incubations included
methyl pyruvate (10 mM) or galactose (Gal, 5 mM). (c) Cells were treated the following nutrient conditions: (1) full-nutrient DMEM; (2) serum-free DMEM; (3) serum- and glucose-
free DMEM; or (4) serum-, glucose- and glutamine-free DMEM, ±CQ (25 μM), as indicated for 24 h, followed by clonogenic viability measurements
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membrane permeabilisation (LMP), in line with previous
data.39 LMP cell death is driven by leakage of cathepsins
from the lysosome, thereby activating caspases or cathepsin-
mediated breakdown of cellular components.62,63 To examine
lysosomal mechanisms, we compared CQ to two other
compounds characterised for LMP. L-Leucyl-L-Leucine methyl
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Figure 6 CQ induces lysosomal swelling, which is blocked upon glucose starvation. (a) 4T1 cells were treated with full-nutrient media (Ctrl); serum starvation; or serum and
glucose starvation±CQ (25 μM) as indicated for 8 h. Cells were fixed and stained for lysosomal-associated membrane protein-1 (LAMP-1). CQ induces robust lysosome
swelling, but this is reversed upon glucose starvation, as highlighted in boxed insets. Scale bar: 10 μm. (b) Quantification of lysosomal size in 4T1 cells described in (a). Average
lysosomal diameters were measured for 30 cells per condition (each cell as a datum point, shown as relative arbitrary units). Reversal of CQ-induced lysosomal swelling by
glucose starvation was conserved in: (c) UVW glioma cells, (d) wild-type MEF and (e) ULK1/2 DKO MEF. (f) 4T1 cells were treated with serum (and glucose starvation) or
alternatively with 2DG (2.5 or 5 mM) ±CQ (25 μM) as indicated for 8 h. Cells were quantified for lysosome swelling. (g) 4T1 cells were treated with full-nutrient media; serum
starvation; or serum and glucose starvation ±CQ (25 μM) as indicated for 4 h. Lysotracker red DND-99 (50 nM) was added for the final 30 min of treatment. Cells were analysed
by confocal microscopy for lysotracker intensity (30 cells per condition). CQ deacidified lysosomes under all nutrient conditions. All data shown are representative of at least three
independent experiments. ***Po0.001 by one-way ANOVA
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Figure 7 CQ cytotoxicity and lysosomal targeting are distinct from doxorubicin and alternate lysosomal membrane permeabilisation and quinoline compounds. (a) 4T1 cells
were treated in full-nutrient media to doxorubicin (200/800 nM) in combination with CQ (25 μM) as indicated for 24 h, followed by the clonogenic survival assay (n= 4 ± S.E.M.).
***Po0.001; **Po0.01 by paired t-test. CQ sensitises to doxorubicin. (b) 4T1 cells were treated to doxorubicin in combination with serum starvation and 2DG (5 mM) as
indicated for 24 h, followed by the clonogenic survival assay (n= 4 ± S.E.M.). 2DG does not provide resistance to doxorubicin. (c and d) 4T1 cells were treated to full-nutrient
media, serum starvation or serum and glucose starvation, in combination with: CQ (25 μM), LLOMe (5 mM) or Cpx (150 μg/ml), for 24 h, followed by assay for survival (n= 3
experiments ± S.E.M.). (e) 4T1 cells were incubated in full-nutrient media (Ctrl) alone or in presence CQ, LLOMe or Cpx for the indicated times (hours) followed by analysis of
LAMP-1 (lysosomal swelling; 30 cells per condition). All imaging data representative of at least three independent experiments. (f) Cells treated in parallel were analysed for
lysotracker red staining. (g and h) 4T1 cells were treated with full-nutrient media; serum starvation; or serum and glucose starvation ±CQ, PQ or AQ (all 25 μM) as indicated, for
24 h, followed by clonogenic cell viability measurements (n= 3 experiments ± S.E.M.). (i) 4T1 cells were analysed for LAMP-1 lysosomal swelling as in (c; 30 cells per condition).
CQ led to the most robust lysosomal swelling. (j) Cells treated in parallel were analysed for lysotracker red staining. CQ, AQ and PQ all rapidly led to lysosome deacidification
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Figure 8 Inhibition of glycolysis rescues CQ-mediated lysosome damage and cell death. (a) 4T1 cells expressing GFP-Galectin3 were treated to CQ (25 μM) in full-nutrient
media or in combination with serum starvation (±2-deoxyglucose (5 mM)) as indicated for 18 h. As control, cells were treated with LLOMe (2.5 mM) for 2 h. Scale bar: 10 μm. (b)
GFP-Galectin3 puncta were quantified in 4T1 cells treated to LLOMe (2.5 mM) or CQ (25 μM) for up to 4 h (50 cells from N= 4 independent samples). (c) GFP-Galectin3 puncta
were quantified in 4T1 cells treated as indicated for 18 h (50 cells from N= 4 independent samples). **Po0.01 by paired t-test. 2DG inhibits lysosomal damage from CQ. (d)
4T1 cells were treated to CQ (25 μM) in full-nutrient media or in combination with serum starvation (±2-deoxyglucose (5 mM)) as indicated for 18 h and nuclei were visualised. As
control, cells were treated with staurosporin (1 μM) for 2 h. Scale bar: 10 μm. (e) Nucleus area was quantified in 4T1 cells treated as indicated for up to 4 h (45–80 cells per
condition, representative of four experiments). (f) Nucleus area in 4T1 cells treated for 4 h (170–230 cells per condition from four experiments). (g) Nucleus area in 4T1 cells
treated for 18 h (190–260 cells per condition from four experiments). ***Po0.001 by paired t-test. 2DG inhibits lysosomal damage from CQ
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ester (LLOMe) becomes converted into a bioactive form
inside the lysosome to cause organellar disruption.64–66 The
quinolone antibiotic ciprofloxacin (Cpx) has been shown to
induce LMP and mitochondrion-dependent cell death.67,68
The control samples here confirmed cytotoxicity from CQ
+serum starvation, which was blocked by glucose starvation
(Figures 7c and d). In contrast, LLOMe cell killing was not
potentiated by serum starvation but was markedly enhanced
only in the context of serum and glucose starvation. Cpx
showed only mild effects on viability in 4T1 cells that was
independent of nutrient starvation conditions.
As these three lysosomal targeting agents displayed
different cytotoxic and nutrient-dependent profiles, we next
interrogated their effects on the lysosome. CQ treatment
induced lysosomal swelling in a time-dependent manner,
progressing in severity over 4 h (Figure 7e). In contrast, neither
LLOMe nor Cpx led to any lysosomal swelling. We further
inspected lysosomal acidification. Both CQ and LLOMe
treatments led to rapid (within 30 min) and complete deacidi-
fication of lysosomes (Figure 7f). In contrast, Cpx did not have
clear effects on Lysotracker staining. In summary, our data
indicate widely distinct profiles of lysosomal targeting by these
lysosomotropic compounds. Only CQ led to time-dependent
lysosomal swelling that was blocked by glucose starvation.
Mechanism of AQ is distinct from CQ and is not glucose-
dependent. CQ belongs to a family of antimalarial quinoline
compounds, and related members are being widely explored
as cancer therapeutics. AQ, a 4-aminoquinoline, and
Primaquine (PQ), a 8-aminoquinoline, have been studied in
melanoma and oral squamous carcinoma.21,69 We ques-
tioned whether these structurally related compounds would
also display an interaction with nutrient starvation (Figures 7g
and h). When compared at equimolar levels, PQ was not
cytotoxic alone but showed mildly increased potency when
combined with serum starvation, although effects were not as
strong as CQ. Furthermore, PQ action was not inhibited upon
further starvation of glucose. By comparison, AQ was more
potent than CQ when used alone and showed further
cytotoxicity when combined with serum starvation. Glucose
starvation did not show any protective rescue towards AQ. In
terms of lysosomal targeting, both PQ and AQ led to similar
time-dependent swelling of the lysosome but effects were not
as robust as compared with CQ (Figure 7i). However, all three
quinolines rapidly de-acidified the lysosome (Figure 7j). In
summary, these three quinoline structural derivatives have
markedly different effects on cell viability and lysosomal
swelling. Furthermore, AQ was most potent in killing 4T1 cells
and this cytotoxicity was not blocked by glucose starvation.
CQ-mediated lysosomal damage and cell death are
glycolysis-dependent. CQ-induced cytotoxicity was depen-
dent on glucose metabolism and our results suggested
lysosome-mediated cell death. To further dissect the
mechanism, we investigated lysosome damage by studying
galectin puncta formation. Galectin members bind to
β-galactoside sugars such as those exposed upon LMP.70
Indeed, 4T1 cells treated with LLOMe formed extensive
puncta of GFP-Galectin3 (Gal3) within 1–2 h of treatment
(Figures 8a and b). Surprisingly, CQ treatment under the
same timeframe did not generate comparably strong Gal3
puncta. However, prolonged CQ treatment led to Gal3-
detectable lysosomal damage, both alone or with serum
starvation (Figure 8c). Blocking glucose flux with 2DG
significantly reduced CQ-dependent lysosome permeabilisa-
tion, both in 4T1 cells and MEF (Supplementary Figure 4).
In parallel, we monitored nuclear morphology, as this
readout correlates with apoptosis and other forms of cell
death. Staurosporin, as a positive control for apoptosis, led to
strong nuclear condensation within 1–2 h of treatment
(Figures 8d and e). In contrast, targeting the lysosome using
LLOMe or CQ produced relatively weaker nuclear condensa-
tion under the same timeframe. CQ treatment combined with
serum starvation led to higher levels of nuclear condensation,
but only after prolonged treatment (Figures 8f and g).
Interestingly, inhibition of glycolysis with 2DG completely
reversed this cell death phenotype caused by CQ and serum
starvation.
Discussion
CQ is widely used in clinical trials, but its mechanism is still
unclear. Although initially studied for DNA binding,71,72 CQ is
better recognised for its properties as a weak base, leading to
uptake and deacidification of the lysosome.25 Block of
lysosomal function thereby stops autophagy membrane
trafficking and degradative flux. On the basis of the role of
autophagy for cell metabolism and survival, the therapeutic
efficacy of CQ in cancer has been widely proposed to be
through autophagy inhibition.
Here, we show that CQ potently sensitises cancer cells to a
number of different stressors, in agreement with the current
clinical applications.2 In contrast, genetic inhibition of autop-
hagy was not able to mimic CQ and drive cell killing.
Autophagy is integral for intracellular quality control and
metabolism.1,5 However, our findings here indicate that
blocking autophagy does not necessarily halt cancer cell
growth. Furthermore, CQ-mediated cell killing was not
modulated when autophagy was blocked, consistent with
other data.26,28
Surprisingly, in exploring nutrient stress, we found that
glucose starvation blocked CQ-mediated cytotoxicity. Inhibi-
tion of glycolysis with 2DG also rescued cells from CQ. In our
working model, CQ enters cells and deacidifies lysosomes
within an hour of treatment. Subsequently, CQ leads to
swelling of lysosomal compartments, which culminated over
time into lysosomal damage and leakiness, thereby triggering
cell death. Glucose starvation (or 2DG) completely prevented
lysosomal swelling, damage and cell death activation. Amino-
acid starvation did not produce a similar rescue effect.
Glucose levels are critical for assembly and function of the
lysosomal vacuolar-ATPase.73 However, lysosomes were
clearly acidified even following glucose starvation, and further
addition of CQ abolished this signal. Therefore, CQ was still
able to target lysosome pH under glucose starvation, but was
unable to drive further swelling and lysosomal damage.
Nonetheless, effects of CQ in patients may be limited inside
the cores of tumours encountering limited vascularisation and
glucose-deprivation metabolic stress.74–76 Thus, glucose
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limitation as a cause of resistance can apply to CQ, as seen
with other chemotherapeutic compounds.77,78
Intriguingly, marked lysosomal swelling was unique to CQ.
The compound LLOMe, which has been widely used to trigger
LMP,64,66 led to more rapid lysosomal damage without
swelling. Furthermore, LLOMe cytotoxicity was not blocked,
but rather, enhanced by glucose starvation. Therefore, CQ
promoted a slower form of LMP distinct from those described
previously.64,67 To identify improved anticancer strategies,
another approach has been to re-purpose CQ-related
antimalarial quinolines.8,21,22,79 Here, we found a clear
structure activity relationship when studying AQ, which
resembles CQ, but with addition of a phenolic group on the
tertiary amine side chain. As AQ had higher cytotoxicity and a
lack of interference by glucose starvation, it may be a more
robust compound with efficacy across the wider spectrum of
cancer metabolic contexts. Interestingly, CQ, AQ and PQ all
seem to target lysosome acidification similarly, but additional
chemical moieties prevent AQ and PQ from producing a
marked lysosomal swelling. We thus highlight how cytotoxicity
is produced via mechanisms that differ between CQ and AQ.
Materials and Methods
Cell culture. 4T1 cells were purchased from the American Type Culture
Collection (ATCC distributed via LGC Standards, Middlesex, UK; ATCC CRL-2539)
and cultured in Dulbecco’s modified eagle medium (DMEM) with 4.5 g/l glucose
(Lonza, Slough, UK, #BE12-614F) supplemented with 10% fetal bovine serum
(Labtech International Ltd, East Sussex, UK, #FCS-SA), 4 mM L-Glutamine (Lonza
#BE17-605E) and 100 U/ml penicillin/streptomycin (Lonza #DE17-602E) in a
humidified incubator with 5% CO2 at 37 °C. Both MEFs and UVW glioma cells
80
were cultured using the same method. Wild-type and ULK1/2 DKO MEF have been
described.38 ATG7 mouse pLKO shRNA (TRCN0000092163) and pLKO scrambled
shRNA (Addgene (#1864)) were used to transduce 4T1 cells, followed by selection
with puromycin.
Clonogenic survival assays. Cells (5 × 103/ml) were plated in six-well cell
culture plates (or in some cases 12 well). 24 h after seeding, fresh full nutrient
growth media was replenished. Following a further 24 h, cells were stimulated for
24 h with the following nutrient starvation conditions ±CQ (25 μM; Sigma-Aldrich
Ltd., Gillingham, UK, #C6628). For serum starvation, full nutrient DMEM was
replaced with DMEM (containing 4.5 g/l glucose, 4 mM L-glutamine and 100 U/ml
penicillin/streptomycin as above) with no FBS. For glucose starvation, we used
glucose-free DMEM media containing 4 mM L-Glutamine (Gibco - Life Technologies
Ltd, Paisley, UK, #11966-025) but lacking FBS and penicillin/streptomycin. For
amino starvation, DMEM was replaced with Earle’s balanced salt solution (EBSS;
Sigma #E2888). We assessed the role of glutamine using serum, glucose and
glutamine-free DMEM (ThermoFisher Scientific- Life Technologies Ltd, Paisley, UK
#A1443001). We also assessed MP (Sigma #371173) and galactose (Sigma
#G0750) as alternative carbon sources. Inhibitors tested in cells were as follows:
2DG (Sigma #D8375); RIP kinase 1 inhibitor Necrostatin-1 (Sigma #N9037);
doxorubicin (Tocris Bioscience, Bristol, UK, #2252) and caspase 3 inhibitor z-DEVD-
FMK (Tocris #2166). We used freshly prepared stock solutions of N-acetyl cysteine
(Sigma #A7250). We compared alternative quinoline compounds: PQ (Sigma
#160393) and AQ (Sigma #A2799) made up in sterile water as vehicle. We
compared effects against LLOMe (Sigma #L7393) and Cpx (Sigma #17850).
To examine ionising irradiation, following 2 h pretreatment with CQ (25 μM) in
normal full-nutrient DMEM, cells were exposed to 1, 4 or 10 Gy doses in an X-Rad
225 irradiator (RPS services, Surrey, UK). Twenty-four hours post stress, media were
replenished. We tested NVP-BEZ-235 at a final concentration range of 50–200 nM,
±CQ, diluted in normal full-nutrient DMEM. After 24 h stress conditions ±CQ, cells
were changed back into full-nutrient DMEM and left to grow for 3 days. At end point,
cells were stained with Giemsa followed by quantitation by solubilising stained cells in
30% acetic acid and measurement of absorbance (560 nm), essentially as
described.29
Western blot analysis. Cell lysates were analysed as described previously38
using the following antibodies: LC3: Mouse monoclonal (clone 5F10; Nanotools
antibodies GmbH, Teningen, Germany, #0231-100); p62/SQSTM1: Guinea pig
polyclonal (Progen Biotechnik GmbH, Heidelberg, Germany, #GP62-C); ATG7:
Rabbit monoclonal (D12B11; Cell Signaling Technologies, New England Biolabs,
Hitchin, UK, 8558); Caspase 3: Rabbit monoclonal (8G10; Cell Signalling #9665);
and PARP: Mouse monoclonal (BD Biosciences, Oxford, UK, #556362).
Microscopy. Cells were plated on glass coverslips (precoated with fibronectin
(Sigma #F1141) in the case of 4T1 cells). After treatments, cells were fixed and
stained using the following antibodies: LC3: Rabbit monoclonal (Cell Signalling
2775); p62/SQSTM1 (as above); or LAMP-1 (CD107a): Rat monoclonal (BD
Biosciences #553792). Cell images were captured by confocal microscopy (Leica,
SP5 (Leica Microsystems Ltd, Milton Keynes, UK); or alternatively by
epifluorescence microscopy; Nikon Eclipse E600 (Nikon UK Limited, Surrey, UK).
To quantify lysosomal size, diameters were measured for 10 lysosomes per cell, 30
cells per condition. Final data shown are representative of at least three
independent experiments.
To detect lysosomal acidification, 4T1 cells were treated as indicated with 50 nM
Lysotracker Red DND-99 (LTR; Thermo Fisher - Life Technologies Ltd, Paisley, UK,
#L7528) added during the final 30 min of incubation. Cells were fixed with
paraformaldehyde and immediately imaged using confocal microscopy. LTR intensity
was quantified within cytoplasmic region of interests. Thirty cells per condition were
analysed and data shown are representative of at least three independent
experiments. To detect lysosomal membrane damage, 4T1 cells or MEF were
transfected with pEGFP-hGal3 (gift from Tamotsu Yoshimori; Addgene (Cambridge,
MA, USA) plasmid #7308066) using Lipofectamine 2000 and studied 24 h later. After
treatments, cells were fixed followed by confocal imaging and quantification of puncta.
To detect condensation of nuclei, cells were stained with Hoescht 33342 after
treatments. Nucleus sizes were quantified from confocal images using Thresholding
and the Analyze Particle function in ImageJ.
For live cell tracking, 4T1 cells were plated in 24-well dishes, treated as indicated
and analysed using Incucyte Zoom (Essen Bioscience, Ltd., Welwyn Garden City,
UK) at standard 5%CO2 at 37 °C, with quantification using Incucyte Cell Confluence
measurements. We measured cell growth over the 24-h starvation stress period
followed by 24 h after replenishment with full-nutrient drug-free media. Data points
are average of two wells from a representative of two experiments.
Statistical analysis. Quantitative data were managed in GraphPad Prism
(GraphPad Software, Inc., La Jolla, CA, USA). We used one-way ANOVA with Tukey
post test or Student’s paired t-test as appropriate.
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